STIPE Therapeutics ApS: Financial statements 2020
CVR: 39691175
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
STIPE Therapeutics ApS (CVR 39691175) has filed annual accounts for 2020. In 2020, the company reported a gross profit of EUR -2,948,722 and a net result of EUR -3,867,652. Equity in the 2020 report amounted to EUR 3,764,412. The solvency ratio was 81.4%. The company had 14 employees in the financial year.
- Gross Profit
- EUR -2,948,722
- Profit/Loss
- EUR -3,867,652
- Equity
- EUR 3,764,412
- Total Assets
- EUR 4,624,935
- Employees
- 14
Official annual report
How creditworthy is STIPE Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
STIPE Therapeutics ApS has published its interim report for the period July 2, 2018 – December 31, 2019.
As of April 6, 2020, Regina Hodits has joined the board of directors of STIPE Therapeutics ApS.
As of April 6, 2020, Natalie Rose Sacks has joined the board of directors of STIPE Therapeutics ApS.
About STIPE Therapeutics ApS
STIPE Therapeutics ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is under bankruptcy. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company's owners include CLAUS OLESEN HOLDING ApS, Novo Holdings A/S and Sunstone Life Science Ventures Fund IV K/S. The company has 5 employees (2018). In 2024, the company reported a gross profit of EUR -842,285 and a net result of EUR 1,448,748 compared with EUR -4,456,130 the year before. Equity in the 2024 report amounted to EUR 1,087,512.